The coronavirus disease 2019 (COVID-19) is widely spread and remains a global pandemic. Limited evidence on the systematic evaluation of the impact of treatment regimens on antibody responses exists.
Technological advancements in the North America Gallbladder Cancer Therapeutics industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technol
Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study.
The objective function values obtained after applying Phase 1 and Phase 2(TDFM) matheuristics are given.The updated treatment days of existing patients obtained from Phase 1 are provided.The experimen
This randomized phase III study compares safety and efficacy of two sequence arms in advanced colorectal cancer: irinotecan and S-1 (IRIS) followed by oxaliplatin containing regimen (arm A), or l-leuc
